MedTrace Logo

CC-42344 Safety Study in Healthy Participants

NCT05202379 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-02-19

Study results available
· View outcomes & findings →

Summary

CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.

Conditions

Interventions

DRUG

Placebo

Placebo capsules

DRUG

CC-42344

CC-42344 capsules

Sponsors & Collaborators

  • Cocrystal Pharma Australia Pty Ltd.

    collaborator UNKNOWN

  • Linear Clinical Research

    collaborator INDUSTRY

  • Cocrystal Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Sam Salman, MD · Linear Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-11
Primary Completion
2023-03-29
Completion
2023-03-29

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05202379 on ClinicalTrials.gov